… therapeutic targets and summarizes currently recommended drugs and promising therapeutic
… be targeted to control the disease in Figure 5 . Although iMCD is a rare and intractable …

… B cell-directed monoclonal antibody therapy is the standard of care in KSHV-MCD, and
anti-IL-6 therapy is the recommended first-line therapy and only treatment of iMCD approved by …

… Several key molecular functions may provide potential therapeutic targets in the management
of Castleman's disease (ie, siltuximab targeting IL‐6, tocilizumab targeting IL‐6R, steroid …

… Candidate novel genomic alterations, dysregulated cell types, and signaling pathways have
also been identified as candidate therapeutic targets. RNA sequencing for viral transcripts …

… signaling as a candidate therapeutic target that could potentially be targeted with JAK inhibitors
… Our discoveries demonstrate the potential for accelerating discoveries for rare diseases …

… are highly effective in many iMCD patients, but additional therapies are required for
refractory cases. Much of the recent progress has been coordinated by the Castleman Disease …

… Anti-IL-6 therapy The advent of monoclonal antibody therapy targeting the IL-6 pathway has
significantly impacted the treatment of patients with idiopathic MCD. Agents that have been …

… this disease process. Thus, our aim was to review all published cases of Castleman disease
… histone methylation-related proteins are being studied as potential therapeutic targets [49]. …

… The PI3K/Akt/mTOR pathway, JAK/STAT3 pathway, and type I IFN as drivers have recently
been identified as important signals and are expected to be therapeutic targets in cases …

… The case presentation aims to illustrate the utility and adequacy of current diagnostic criteria
and treatment options recommended by the Castleman Disease Collaborative Network (…